Abnormalities of adhesion molecules and chemokines in scleroderma

Current Opinion in Rheumatology

Volumn 11, Issue 6, 1999, Pages 503-507

  Sato, Shinichi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ADHESION MOLECULE; CHEMOKINE;

CELL ADHESION; CELL INTERACTION; ENDOTHELIUM CELL; FIBROBLAST; HUMAN; IMMUNOPATHOGENESIS; LEUKOCYTE MIGRATION; PRIORITY JOURNAL; REVIEW; SCLERODERMA; T LYMPHOCYTE ACTIVATION;

EID: 0032703621     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-199911000-00010     Document Type: Review

References (43)

1. Fleischmajer R, Ferlish JS, Reeves JRT: Cellular infiltrates in scleroderma skin. Arthritis Rheum 1977, 20:975-984.
2. Scharffetter K, Lankat-Buttgereit B, Krieg T: Localization of collagen mRNA in normal and scleroderma skin by in-situ hybridization. Eur J Clin Invest 1988, 18:9-17.
3. Roumm AD, Whiteside TL, Medsger TA, Rodnan GP: Lymphocytes in the skin of patients with progressive systemic sclerosis: quantification, subtyping, and clinical correlations. Arthritis Rheum 1984, 27:645-653.
4. Abraham D, Lupoli S, McWhirter A, Plater-Zyberk C, Piela TH, Korn JH, Olsen I, Black C: Expression and function of surface antigens on scleroderma fibroblasts. Arthritis Rheum 1991, 34:1164-1172.
5. Ebnet K, Kaldjian EP, Anderson AO, Shaw S: Orchestrated information transfer underlying leukocyte endothelial interactions. Annu Rev Immunol 1997, 14:155-177.
6. Springer TA: Traffic signals on endothelium for lymphocyte recirculation and leukocyte emigration. Annu Rev Physiol 1995, 57:827-872.
7. Butcher EC: Leukocyte-endothelial cell recognition: three (or more) steps to specificity and diversity. Cell 1991, 67:1033-1036.
8. Sfikakis PP, Tsokos GC: Clinical use of the measurement of soluble cell adhesion molecules in patients with autoimmune rheumatic diseases. Clin Diagn Lab Immunol 1997, 4:241-246.
9. Gruschwitz MS, Vieth G: Up-regulation of class II major histocompatibility complex and intercellular adhesion molecule 1 expression on scleroderma fibroblasts and endothelial cells by interferon-γ and tumor necrosis factor α in the early disease stage. Arthritis Rheum 1997, 40:540-550.
10. Gruschwitz MS, Hornstein OP, von den Driesch P: Correlation of soluble adhesion molecules in the peripheral blood of scleroderma patients with their in situ expression and with disease activity. Arthritis Rheum 1995, 38:184-189.
11. Sollberg S, Peltonen J, Uitto J, Jimenez SA: Elevated expression of β1 and β2 integrins, intercellular adhesion molecule 1, and endothelial leukocyte adhesion molecule 1 in the skin of patients with systemic sclerosis of recent onset. Arthritis Rheum 1992, 35:290-298.
12. Gruschwitz M, von den Driesch P, Kellner I, Hornstein OP, Sterry W: Expression of adhesion proteins involved in cell-cell and cell-matrix interactions in the skin of patients with progressive systemic sclerosis. J Am Acad Dermatol 1992, 27:169-177.
13. Koch AE, Kronfeld-Harrington LB, Szekanecz Z, Cho MM, Haines GK, Harlow LA, Stricter RM, Kunkel SL, Massa MC, Barr WG, Jimenez SA: In situ expression of cytokines and cellular adhesion molecules in the skin of patients with systemic sclerosis. Pathobiology 1993, 61:239-246.
14. Hebbar M, Gillot J-M, Hachulla E, Lassalle P, Hatron P-Y, Devulder B, Janin A: Early expression of E-selectin, tumor necrosis factor α, and mast cell infiltration in the salivary glands of patients with systemic sclerosis. Arthritis Rheum 1996, 39:1161-1165.
15. Denton CP, Bickerstaff MCM, Shiwen X, Carulli MT, Haskard DO, Dubois RM, Black CM: Serial circulating adhesion molecule levels reflect disease severity in systemic sclerosis. Br J Rheumatol 1995, 34:1048-1054.
16. Sfikakis PP, Tesar J, Baraf H, Lipnick R, Klipple G, Tsokos GC: Circulating intercellular adhesion molecule-1 in patients with systemic sclerosis. Clin Immunol Immunopathol 1993, 68:88-92.
17. Ihn H, Sato S, Fujimoto M, Kikuchi K, Kadono T, Temaki K, Takehara K: Circulating intercellular adhesion molecule-I in the sera of patients with systemic sclerosis: enhancement by inflammatory cytokines. Br J Rheumatol 1997, 36:1270-1275.
18. Ihn H, Sato S, Fujimoto M, Takehara K, Tamaki K: Increased serum levels of soluble vascular cell adhesion molecule-1 and E-selectin in patients with systemic sclerosis. Br J Rheumatol 1998, 37:1188-1192. Increased serum levels of sVCAM-1 and sE-selectin suggest that EC activation in vivo is involved in the development of SSc.
19. Stratton RJ, Coghlan JG, Pearson JD, Burns A, Sweny P, Abraham DJ, Black CM: Different patterns of endothelial cell activation in renal and pulmonary vascular disease in scleroderma. Q J Med 1998, 91:561-566. Renal vascular lesions were associated with EC activation in vivo, which was reflected by elevated serum levels of endothelial adhesion molecules. whereas pulmonary vascular lesions did not exhibit the phenotype of EC activation. This suggests that these vascular lesions arise by distinct pathogenic mechanisms.
20. Veale DJ, Kirk G, McLaren M, Belch JJF: Clinical implications of soluble intercellular adhesion molecule-1 levels in systemic sclerosis. Br J Rheumatol 1998, 37:1227-1228. This brief article suggests that hypoxic stimulus mainly caused by Raynaud'S phenomenon affects ICAM-1 expression on EC.
21. Leeuwenberg JFM, Smeets EF, Neefjes JJ, Shatter MA, Cinek T: E-selectin and intercellular adhesion molecule-1 are released by activated human endothelial cells in vitro. Immunology 1992, 77:543-549.
22. Søndergaard K, Stengaard-Pedersen K, Zachariae H, Heickendorff L, Deleuran M, Deleuran B: Soluble intercellular adhesion molecule-t (sICAM-1) and soluble interleukin-2 receptors (sIL-2R) in scleroderma skin. Br J Rheumatol 1998, 37:304-310. This work demonstrated elevated levels of sICAM-1 and sIL-2R in skin suction blister fluid, suggesting activation of EC and T cells in both the transition zone and uninvolved skin of patients with SSc.
23. Søndergaard K, Heickendorff L, Risteli L, Risteli J, Zachariae H, Stengaard-Pedersen K, et al.; Increased levels of type I and III collagen and hyaluronan in scleroderma skin. J Rheumatol 1997, 136:47-56.
24. Becjer JC, Termeer C, Schmidt RE, Brocker EB: Soluble intercellular adhesion molecule-1 inhibits MHC-restricted specific T cell/tumor interaction. J Immunol 1993, 151:7224-7232.
25. Welder CA, Lee DHS, Takei F: Inhibition of cell adhesion by microspheres coated with recombinant soluble intercellular adhesion molecule-1. J Immunol 1993, 150:2203-2210.
26. Shi-wen X, Panesar M, Vancheeswaran R, Mason J, Haskard D, Black C, et al.: Expression and shedding of intercellular adhesion molecule 1 and lymphocyte function-associated antigen 3 by normal and scleroderma fibroblasts: effects of interferon-γ, tumor necrosis factor α, and estrogen. Arthritis Rheum 1994, 37:1689-1697.
27. Hasegawa M, Sato S, Takehara K: Augmented production of chemokines (MCP-1, MIP-1α, and MIP-1β) in patients with systemic sclerosis: MCP-1 and MIP-1 α may be involved in the development of pulmonary fibrosis. Clin Exp Immunol 1999, 117:159-165. The results of this study suggest that MCP-1, MIP-1α, and MIP-1β are involved in the disease process, possibly by recruiting specific leukocyte subsets into the affected tissues in SSc, such as the skin and lungs.
28. Denton CP, Shi-Wen X, Sutton A, Abraham DJ, Black CM, Pearson JD: Scleroderma fibroblasts promote migration of mononuclear leukocytes across endothelial cell monolayers. Clin Exp Immunol 1998, 114:293-300. This study demonstrates that MCP-1 is responsible for SSc fibroblast-induced promotion of leukocyte migration across the EC. Promotion of leukocyte migration does not appear to result from increased endothelial adhesion molecules, such as ICAM-1, VCAM-1, and E-selectin, Although MCP-1 may be mainly of fibroblast origin, the source of MCP-1 cannot be directly determined in this study.
29. Kadono T, Kikuchi K, Ihn H, Takehara K, Temaki K: Increased production of interleukin 6 and interleukin 8 in scleroderma fibroblasts. J Rheumatol 1998, 25:296-301.
30. Baggiolini M, Dewald B, Moser B: Human chemokines: an update. Annu Rev Immunol 1997, 15:675-705.
31. Luster AD: Chemokines - chemotactic cytokines that mediate inflammation. N Eng J Med 1998, 338:436-445.
32. Bolster MB, Ludwicka A, Sutherland SE, Strange C, Silver RM: Cytokine concentrations in bronchoalveolar lavage fluid of patients with systemic sclerosis. Arthritis Rheum 1997, 40:746-751.
33. Kraling BM, Maul GG, Jimenez SA: Mononuclear cellular infiltrates in clinically involved skin from patients with systemic sclerosis of recent onset predominantly consist of monocytes/macrophages. Pathobiology 1995, 63:48-56.
34. Giacomelli R, Matucci-Cerinic M, Cipriani P, Ghersetich I, Lattanzio R, Pavan A, et al,: Circulating Vδ1+ T cells are activated and accumulate in the skin of systemic sclerosis patients. Arthritis Rheum 1998, 41:327-334.
35. Needleman BW: Increased expression of intercellular adhesion molecule 1 on the fibroblasts of scleroderma patients. Arthritis Rheum 1990, 33:1847-1851.
36. Majewski S, Hunzelmann N, Johnson JP, Jung C, Mauch C, Ziegler-Heitbrock HWL, et al.: Expression of intercellular adhesion molecule-1 (ICAM-1) in the skin of patients with systemic sclerosis. J Invest Dermatol 1991, 97:667-671.
37. Shi-wen X, Denton CP, Dashwood MR, Abraham DJ, Black GM: Endothelin-1 regulation of intercellular adhesion molecule-1 expression in normal and sclerodermal fibroblasts. J Cardiovasc Pharmacol 1998, 31 (suppl):S545-S547. This study demonstrates that endothelin-1 can upregulate ICAM-1 expression on fibroblasts, providing a novel mechanism by which endothelin-1 is involved in the development of fibrosis.
38. Vancheeswaran R, Azam A, Black CM, Dashwood MR: Localization of endothelin-1 and its binding sites in scleroderma skin. J Rheumatol 1994, 21:1268-1276.
39. Abraham DJ, Vancheeswaran R, Dashwood MR, Rajkumar VS, Pantelides P, Shi-wen X, et al.: increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease. Am J Pathol 1997, 151:831-841.
40. Yamane K, Miyauchi T, Suzuki N, Yuhara T, Akama T, Suzuki H, et al.: Significance of plasma endothelin. 1 levels in patients with systemic sclerosis. J Rheumatol 1992, 19;1566-1571.
41. Chizzolini C, Ressonico R, Ribbens C, Burger D, Wollheim FA, Dayer J-M: inhibition of type I collagen production by dermal fibroblasts upon contact with activated T cells: different sensitivity to inhibition between systemic sclerosis and control fibroblasts. Arthritis Rheum 1998, 41:2039-2047.
42. Mojcik CF, Shevach EM: Adhesion molecules: a rheumatologic perspective. Arthritis Rheum 1997, 40:991-1004.
43. Sfikakis PP, Tsokos GC: Lymphocyte adhesion molecules in autoimmune rheumatic diseases: basic issues and clinical expectations, Clin Exp Rheumatol 1995, 13:763-777.